LEQVIO

targets

all catalysts(0)

nothing on the calendar yet

News(7)

• Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters
  Novartis’ recent dual clinical setbacks have prompted questions from a major shareholder about the board’s oversight of dealmaking.
  fiercebiotech · 24d ago
• Scribe’s early-stage IPO standout defies biotech’s derisking trend
  Scribe Therapeutics’ one-time epigenetic treatment is designed to slash the adherence burden of chronic cholesterol-lowering therapies while sidestepping the irreversibility of gene editing.
  biospace · 1mo ago
• Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses
  The CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years.
  biopharma_dive · 1mo ago
• Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds
  In vivo gene editing outfit Scribe Therapeutics has priced its IPO at $128.7 million, surpassing the $96 million goal set out earlier this week.
  fiercebiotech · 2mo ago
• Novartis climbs on upbeat drug sales as key readouts loom
  A return to quarterly sales growth boosted shares higher on Tuesday, though a handful of coming study results will have a bigger impact on the company’s long-term outlook.
  biopharma_dive · 2mo ago
• Scribe aims for $96M IPO to fund clinical push for lipid-lowering genetic meds
  Scribe Therapeutics has put its IPO plans down on paper, showing the genetic medicine company hopes to raise $96 million through its public listing.
  fiercebiotech · 2mo ago
• Merck dives into cholesterol with first FDA approval for oral PCSK9 inhibitor
  Merck’s once-daily pill is the first oral PCSK9 inhibitor to hit the market for high cholesterol, beating AstraZeneca in the race to develop more accessible treatment options.
  biospace · 2mo ago